Integra LifeSciences (NASDAQ:IART) Stock Price Down 11.9% - Should You Sell?

Key Points

• Integra LifeSciences' stock price dropped 11.9% to $11.58, down from a previous close of $13.14, with trading volume decreasing by 37% from its average.
• Several analysts have reduced their price targets for the stock, with Wells Fargo lowering it from $25.00 to $13.00 and JPMorgan from $24.00 to $12.00, leading to a consensus rating of "Hold."
• Despite beating earnings expectations with a reported $0.45 EPS, Integra's revenue was down 0.6% year-over-year, highlighting ongoing operational challenges.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) shares dropped 11.9% during trading on Friday . The stock traded as low as $11.64 and last traded at $11.58. Approximately 613,484 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 980,313 shares. The stock had previously closed at $13.14.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Performance

The firm's 50-day moving average price is $12.60 and its two-hundred day moving average price is $17.63. The firm has a market capitalization of $956.61 million, a PE ratio of -1.89, a P/E/G ratio of 0.69 and a beta of 1.16. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 11.18%. The business had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same period in the previous year, the company earned $0.63 earnings per share. Integra LifeSciences's revenue for the quarter was down .6% on a year-over-year basis. As a group, research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaQuest LLC acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $73,000. Caitong International Asset Management Co. Ltd increased its position in Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock valued at $38,000 after purchasing an additional 2,108 shares during the period. Allianz Asset Management GmbH lifted its holdings in shares of Integra LifeSciences by 53.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 229,904 shares of the life sciences company's stock worth $2,821,000 after purchasing an additional 80,290 shares in the last quarter. New York State Teachers Retirement System lifted its stake in Integra LifeSciences by 1.9% during the 2nd quarter. New York State Teachers Retirement System now owns 87,660 shares of the life sciences company's stock valued at $1,076,000 after acquiring an additional 1,662 shares in the last quarter. Finally, CWM LLC increased its position in shares of Integra LifeSciences by 32.6% during the 2nd quarter. CWM LLC now owns 8,834 shares of the life sciences company's stock valued at $108,000 after purchasing an additional 2,170 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.